coflex Interlaminar Technology
Companion Spine France · Decision date May 22, 2026
What did the FDA approve?
FDA records P110008/S015 as a supplement to PMA P110008, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 22, 2026.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested termination of study enrollment and subject follow-up for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P110008. Based upon the information submitted, the PMA supplement is approved.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Orthopedic
- Decision date
- May 22, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P110008/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Companion Spine France
- Product code
- NQO
- Decision code
- APPR
- Decision date
- May 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, spinous process spacer/plate.
- Applicant
- Companion Spine France
- Product code
- NQO
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110008/S015 received
Application receipt date recorded by FDA.
P110008/S015 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P110008. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NQO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DIAM Spinal Stabilization SystemP240043/S001 | Companion Spine France Sas | PMA supplement | Apr 1, 2026 | FDA |
| Companion Spine France Sas | PMA approval | Dec 10, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Companion Spine France
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Immeuble Le Bridge - 5 Allee Des Acacias, Merignac Gironde, 33700
Sources and methodology
- Original FDA record: P110008/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
